374P: Prognostic relevance of post-cycle 1 pembrolizumab levels in real-world NSCLC patients receiving first line IO or ChIO.

Authors: Martinez, C., Alejandre, M. Molina, De Juan, V. Calvo, Lorduy, A. Collazo, Estevez, S. Vazquez, Nunez, N. Fernandez, Tain, P. Diz, Onecha, M.L. Garrido, Banaclocha, N. Martinez, Peña, E., Jiménez-Meseguer, M., Martin, A. Lopez, Cabia, S. Peña, Lopez, S. Sequero, Rogado, J., Hernandez, A. Sanchez, Sarto, J. Coves, Gonzalez, M.A. Sala, Cruz-Bermudez, A., Pulla, M. Provencio

Source: Journal of Thoracic Oncology; 2025 Supplement 1, Vol. 20, pS220-S221, 2p